Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study
Sponsor: Changzhou Second People's Hospital
This observational or N/A phase trial investigates Metabolic Associated Fatty Liver Disease and Type 2 Diabetes Mellitus in Remission and is currently actively recruiting participants. Changzhou Second People's Hospital leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Feb 2023 — Jul 2024 [monthly]
Recruiting
-
Nov 2022 — Feb 2023 [monthly]
Recruiting
First recorded
Jul 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changzhou Second People's Hospital
- Huaian Hospital
- Huaian Second People's Hospital
- Huaian Xuyi County People's Hospital
- Nantong First People's Hospital
- Suzhou Fifth People's Hospital
- Suzhou Municipal Hospital
- Taizhou Jiangyan Traditional Chinese Medicine Hospital
- Wuxi Hisky Medical Technology Co Ltd
- Xuzhou Mining Group General Hospital
- Yangzhou Jiangdu People's Hospital
- Zhongda Hospital
For direct contact, visit the study record on ClinicalTrials.gov .